先进光伏器件中试平台打通科技成果转化"最后一公里"。 天府绛溪实验室加速开展关键技术攻关与产业转化。 联合四川新先达测控技术有限公司，产学研协同开发国产全链路信号与系统仿真软件"NESIM-A"（纽西蒙）；西南首个先进能源材料基因工 程融合创新（中试）平台正开展验证，助推固态电池材料从实验室走向产业化……走进天府绛溪实验室，一幕幕科研攻关的场景正是成都高新 区科产深度融合的生动缩影。 1月28日，成都市第十八届人民代表大会第四次会议开幕，代市长陈书平代表成都市人民政府向大会作政府工作报告。报告提出，坚持科产融 合、壮大新质生产力，全力推动重点产业聚链成群。 作为成都科技创新的核心承载地和产业发展主阵地，成都高新区如何持续深化科产融合、激活创新动能，让新质生产力在这片创新沃土上加速 生长、结出更多硕果，加快建设世界领先科技园区？ 转自：成都日报锦观 让科技成果加速奔向生产线 成都高新区科产融合向"新"而行 新研机构筑基 "四张清单"释放创新策源力 在成都未来科技城，天府绛溪实验室的科研人员正围绕具身智能、电磁感知、泛在互联等领域开展攻关，实验室孵化招引的多家企业整体估值 已突破7亿元。 天府绛溪实验室由四川省政 ...

Core Insights - Rui Jian Pharmaceutical has achieved significant milestones in the development of its Parkinson's disease cell therapy product NouvNeu001, becoming the first globally to receive Fast Track designation from the FDA and entering Phase II clinical trials in China [1][4] - Chengdu High-tech Zone is emerging as a key player in the biopharmaceutical industry, with a focus on innovative drug development and a robust ecosystem supporting various companies [3][12] Company Developments - Rui Jian Pharmaceutical's NouvNeu001 is the first iPSC-derived universal cell therapy for Parkinson's disease to gain Fast Track status from the FDA, while also progressing in clinical trials in China [1] - The company is also advancing other products, such as NouvNeu004 for multiple system atrophy, which has received approval for full-cycle clinical trials in China [4] - Recent funding of over 300 million yuan for Rui Jian Pharmaceutical will accelerate the development of its Parkinson's and ophthalmic treatment products [14] Industry Trends - Chengdu High-tech Zone has been recognized as a leading biopharmaceutical hub, ranking alongside other major innovation districts in China [3] - The region is witnessing a surge in innovative products, with multiple companies achieving significant breakthroughs in various therapeutic areas, including diabetes and cancer [7][5] - The biopharmaceutical industry in Chengdu is projected to exceed 128 billion yuan in scale by 2024, with over 3,000 companies contributing to this growth [7] Ecosystem and Collaboration - The development of Rui Jian Pharmaceutical is closely tied to the supportive ecosystem in Chengdu High-tech Zone, which includes a network of suppliers and clinical resources [8][10] - The establishment of the "Global New Drug Discovery Center" aims to integrate resources from over 3,000 biopharmaceutical companies in the region, enhancing collaboration and innovation [11] - The collaboration between enterprises and institutions, such as Sichuan University West China Hospital, is fostering a comprehensive innovation chain from research to commercialization [12][18] Policy and Financial Support - Chengdu High-tech Zone has implemented supportive policies and established a substantial investment fund to facilitate the growth of the biopharmaceutical sector [16][17] - The "Wutong Plan" provides a comprehensive service framework for biopharmaceutical companies, covering all stages from drug development to market entry [17] - The region's proactive approach in policy-making and capital investment is crucial in overcoming challenges in the biopharmaceutical innovation landscape [16][14]